Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Inclusion Criteria: * Histologic diagnosis of primary or de novo MDS using WHO classification * Non-del(5q) low or Intermediate-1risk MDS * ECOG performance status of 0-1 * Documented significant cytopenia for at least 2 months * Must have discontinued growth factors (EPO, G-CSF, GM-CSF) for at least 21 days prior to study entry * All study participants must be registered into the mandatory RevAssist® program and be willing and able to comply with the requirements of RevAssist® * Females of childbearing potential should have two negative serum pregnancy tests with a sensitivity of at least 50 mIU/mL. The first test should be performed within 10-14 days, and the second test within 24 hours of prescribing lenalidomide (prescriptions must be filled within seven days) Exclusion Criteria: * Known hypersensitivity to Telintra™ (intravenous or oral) * Known prior therapy with or hypersensitivity to thalidomide or lenalidomide * Prior allogenic bone marrow transplant for MDS * History or prior malignancy * Except for treated carcinoma of uterine cervix, basal cell or squamous cell skin cancer, or other cancers (e.g. breast, prostate) for which patient has been disease-free for at least 3 years. * MDS evolving from: * A pre-existing myeloproliferative disorder * An autoimmune disease * Secondary to prior treatment with radiation or chemotherapy * History of MDS IPSS score\>1.0 * Pregnant or lactating women * Leptomeningeal or leukemic meningitis * Prior treatment with DNA methyltransferase inhibitors (DMTI) \[e.g., azacitadine, decitabine, etc.\]